These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 12823906)

  • 1. Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis.
    Grimbert D; Vecellio L; Delépine P; Attucci S; Boissinot E; Poncin A; Gauthier F; Valat C; Saudubray F; Antonioz P; Diot P
    J Aerosol Med; 2003; 16(2):121-9. PubMed ID: 12823906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis.
    Attucci S; Gauthier A; Korkmaz B; Delépine P; Martino MF; Saudubray F; Diot P; Gauthier F
    J Pharmacol Exp Ther; 2006 Aug; 318(2):803-9. PubMed ID: 16627747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of neutrophil elastase and its inhibitor EPI-hNE4 on transepithelial sodium transport across normal and cystic fibrosis human nasal epithelial cells.
    Prulière-Escabasse V; Clerici C; Vuagniaux G; Coste A; Escudier E; Planès C
    Respir Res; 2010 Oct; 11(1):141. PubMed ID: 20932306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis.
    Laube BL; Geller DE; Lin TC; Dalby RN; Diener-West M; Zeitlin PL
    Respir Care; 2005 Nov; 50(11):1438-44. PubMed ID: 16253150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aerosol delivery of recombinant human DNase I: in vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer.
    Johnson JC; Waldrep JC; Guo J; Dhand R
    Respir Care; 2008 Dec; 53(12):1703-8. PubMed ID: 19025706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung deposition and respirable mass during wet nebulization.
    Sangwan S; Condos R; Smaldone GC
    J Aerosol Med; 2003; 16(4):379-86. PubMed ID: 14977428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor.
    Delacourt C; Hérigault S; Delclaux C; Poncin A; Levame M; Harf A; Saudubray F; Lafuma C
    Am J Respir Cell Mol Biol; 2002 Mar; 26(3):290-7. PubMed ID: 11867337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology.
    Li Z; Perkins W; Cipolla D
    Eur J Pharm Biopharm; 2021 Sep; 166():10-18. PubMed ID: 34082122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate.
    Laube BL; Jashnani R; Dalby RN; Zeitlin PL
    Chest; 2000 Oct; 118(4):1069-76. PubMed ID: 11035679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reconciliation of Cascade Impaction during Wet Nebulization.
    Solomita M; Smaldone GC
    J Aerosol Med Pulm Drug Deliv; 2009 Mar; 22(1):11-8. PubMed ID: 19392585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer.
    Le Brun PP; de Boer AH; Gjaltema D; Hagedoorn P; Heijerman HG; Frijlink HW
    Int J Pharm; 1999 Nov; 189(2):205-14. PubMed ID: 10536249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerosol deposition in infants with cystic fibrosis.
    Mallol J; Rattray S; Walker G; Cook D; Robertson CF
    Pediatr Pulmonol; 1996 May; 21(5):276-81. PubMed ID: 8726152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.
    Rottier BL; van Erp CJ; Sluyter TS; Heijerman HG; Frijlink HW; Boer AH
    J Aerosol Med Pulm Drug Deliv; 2009 Sep; 22(3):263-9. PubMed ID: 19466906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of aerosol deposition by pressure support in children with cystic fibrosis: an experimental and clinical study.
    Fauroux B; Itti E; Pigeot J; Isabey D; Meignan M; Ferry G; Lofaso F; Willemot JM; Clément A; Harf A
    Am J Respir Crit Care Med; 2000 Dec; 162(6):2265-71. PubMed ID: 11112150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of positive expiratory pressure devices attached to nebulizers.
    Berlinski A
    Respir Care; 2014 Feb; 59(2):216-22. PubMed ID: 23920213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal evaluation of compressor/nebulizer performance.
    Awad S; Williams DK; Berlinski A
    Respir Care; 2014 Jul; 59(7):1053-61. PubMed ID: 24149670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of nebulizer type with different pediatric aerosol masks on drug deposition in a model of a spontaneously breathing small child.
    Lin HL; Wan GH; Chen YH; Fink JB; Liu WQ; Liu KY
    Respir Care; 2012 Nov; 57(11):1894-900. PubMed ID: 22418694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols.
    Alexander BD; Winkler TP; Shi S; Dodds Ashley ES; Hickey AJ
    Pharm Dev Technol; 2011; 16(6):577-82. PubMed ID: 21699390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging the postdeposition dispersion of an inhaled surfactant aerosol.
    Corcoran TE; Thomas KM; Garoff S; Tilton RD; Przybycien TM; Pilewski JM
    J Aerosol Med Pulm Drug Deliv; 2012 Oct; 25(5):290-6. PubMed ID: 22393908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow Marple personal cascade impactor.
    Kwong WT; Ho SL; Coates AL
    J Aerosol Med; 2000; 13(4):303-14. PubMed ID: 11262437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.